A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib
{{output}}
KRASG12C is one of the most common oncogenes in non-small cell lung cancer (NSCLC) and is associated with a poor prognosis. Historically, KRAS mutations have been difficult to target due to lack of binding sites and exceptionally high affinity for guanosine tr... ...
